Aflibercept in Clinical Practice

1. Bressler, S.B., Bressler, N.M., Fine, S.L. et al.: Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol, 93(2); 1982: 157–163.

2. Congdon, N., O’Colmain, B., Klaver, C.C. et al.: Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol, 122 (4); 2014: 477–485.

3. Heier, J.S., Brown, M.D., Chong, V. et al.: Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology, 119 (12); 2012: 2537–2548.

4. Chang, A.A., Li, H., Broadhead, G.K. et al.: Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology, 121; 2014: 188–192.

5. Cho, H., Weber, M.L., Shah, C.P. et al.: Initial utilization of aflibercept in exudative age related macular degeneration. Eur J Ophthalmol, 24(4); 2014: 576–581.

6. Martin, D.F., Maguire, M.G., Ying, G.S. et al: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med, 364(20); 2011: 1897–1908.

7. Papadopoulos, N., Martin, J., Ruan, Q. et al.: Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis, 15(2); 2012: 171–185.

8. Resnikoff, S., Pascolini, D., Etya’ale, D. et al.: Global data on visual impairment in the year 2002, Bull World Health Organ, 82(11); 2004: 844–851.

9. Rudge, J.S., Holash, J., Hylton, D. et al.: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A, 104(47); 2007: 18363–18370.

10. Sawa, Y. et al.: Short-term outcomes of aflibercept for recurrent neovascular age-related macular degeneration in Japanese patients. E-poster PO-1531, World Ophthalmology Congress 2014, Tokyo, Japan, April 2–6, 2014.

11. Schmidt-Erfurth, U. et al.: Intravitreal aflibercept injection for neovascular age-related macular degeneration. Ninety-six week results of the VIEW studies. Ophthalmology, 121; 2014: 193–201.

12. Schmier, J.K., Jones, M.L., Halpern, M.T.: The burden of age-related macular degeneration. Pharmacoeconomics, 24(4); 2006: 319–334.

13. Soubrane, G., Cruess, A., Lotery, A. et al.: Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol, 125(9); 2007: 1249–1254.

14. Eylea (aflibercept injekčný roztok v liekovke) Súhrn charakteristických vlastností lieku. Berlin, Nemecko: Bayer Pharma AG: 2014.

15. Wykoff, C.C., Brown, D.M., Maldonado, M.E. et al.: Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol, 98(7); 2014: 951–955.

16. Yonekawa, Y., Andreoli, C., Miller, J.B. et al.: Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol, 156(1); 2013: 29–35.